SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,290.45 |
Enterprise Value ($M) | 1,240.45 |
Book Value ($M) | -167.00 |
Book Value / Share | -1.31 |
Price / Book | -7.73 |
NCAV ($M) | -832.00 |
NCAV / Share | -6.54 |
Price / NCAV | -1.55 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.03 |
Return on Assets (ROA) | -0.00 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.65 |
Current Ratio | 0.83 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 799.00 |
Assets | 1,464.00 |
Liabilities | 1,631.00 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Flynn James E | 5.80 | ||
13G/A | Scopia Capital Management Lp | 4.30 | -51.80 | |
13D/A | Oaktree Capital Holdings, LLC | 7.50 | 1.56 | |
13D/A | Two Seas Capital LP | 10.10 | -1.73 | |
13G | SG Americas Securities, LLC | 5.17 | ||
13G | Morgan Stanley | 7.10 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
72,178 | 443,824 | 16.26 | |
40,556 | 277,531 | 14.61 | |
35,856 | 355,630 | 10.08 | |
115,165 | 671,304 | 17.16 | |
72,793 | 467,081 | 15.58 | |
(click for more detail) |
Similar Companies | |
---|---|
IMUX – Immunic, Inc. | IMVT – Immunovant, Inc. |
INBX – Inhibrx Biosciences, Inc. | INNV – InnovAge Holding Corp. |
INSM – Insmed Incorporated |
Financial data and stock pages provided by
Fintel.io